# Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutations

> **NCT02352844** · PHASE2 · COMPLETED · sponsor: **Washington University School of Medicine** · enrollment: 12 (actual)

## Conditions studied

- Solid Malignancy
- Solid Tumor

## Interventions

- **DRUG:** Everolimus

## Key facts

- **NCT ID:** NCT02352844
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10-07
- **Primary completion:** 2017-08-15
- **Final completion:** 2017-08-15
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2018-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02352844

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02352844, "Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutations". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02352844. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*